139 related articles for article (PubMed ID: 21068091)
1. The need for personalised medicine for rheumatoid arthritis.
Isaacs JD; Ferraccioli G
Ann Rheum Dis; 2011 Jan; 70(1):4-7. PubMed ID: 21068091
[TBL] [Abstract][Full Text] [Related]
2. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Belmonte Serrano MA; Pincus T
Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342
[No Abstract] [Full Text] [Related]
3. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
[TBL] [Abstract][Full Text] [Related]
4. Predictors of response to TNF inhibitors in rheumatoid arthritis - do we have new tools for personalized medicine?
Simsek I
Bull NYU Hosp Jt Dis; 2012; 70(3):187-90. PubMed ID: 23259626
[TBL] [Abstract][Full Text] [Related]
5. Personalised treatment of arthritis in the next eRA.
Tas SW
Neth J Med; 2009 Dec; 67(11):362-3. PubMed ID: 20009111
[No Abstract] [Full Text] [Related]
6. Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature.
Ingegnoli F; Favalli EG; Meroni PL
Autoimmun Rev; 2011 Jun; 10(8):460-3. PubMed ID: 21296193
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
[TBL] [Abstract][Full Text] [Related]
8. State-of-the-art: rheumatoid arthritis.
McInnes IB; O'Dell JR
Ann Rheum Dis; 2010 Nov; 69(11):1898-906. PubMed ID: 20959326
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.
Miossec P; Verweij CL; Klareskog L; Pitzalis C; Barton A; Lekkerkerker F; Reiter S; Laslop A; Breedveld F; Abadie E; Flamion B; Dere W; Mpofu S; Goel N; Ethgen D; Mitlak B; Ormarsdóttir S; Rao R; Tsouderos Y; Reginster JY;
Ann Rheum Dis; 2011 Oct; 70(10):1713-8. PubMed ID: 21784723
[TBL] [Abstract][Full Text] [Related]
10. [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland].
Samborski W; Buczek J; Bednarek A; Lewandowicz J; Kucharz E
Pol Merkur Lekarski; 2010 Dec; 29(174):365-8. PubMed ID: 21298986
[TBL] [Abstract][Full Text] [Related]
11. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
Baslund B; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
[TBL] [Abstract][Full Text] [Related]
12. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
13. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
Gerlag DM; Tak PP
Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
Choy E
Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
[TBL] [Abstract][Full Text] [Related]
16. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents.
Ranganathan P
Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134
[TBL] [Abstract][Full Text] [Related]
17. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis.
Vosslamber S; Raterman HG; van der Pouw Kraan TC; Schreurs MW; von Blomberg BM; Nurmohamed MT; Lems WF; Dijkmans BA; Voskuyl AE; Verweij CL
Ann Rheum Dis; 2011 Jun; 70(6):1153-9. PubMed ID: 21444302
[TBL] [Abstract][Full Text] [Related]
20. Infliximab treatment of rheumatoid arthritis.
Maini SR
Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
